VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 200 filers reported holding VAXCYTE INC in Q4 2022. The put-call ratio across all filers is 0.72 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,386,629 | +8.0% | 46,815 | +5.8% | 0.02% | +15.4% |
| Q2 2023 | $2,209,945 | +70.4% | 44,252 | +27.8% | 0.01% | +44.4% |
| Q1 2023 | $1,297,295 | -20.2% | 34,613 | +2.0% | 0.01% | -18.2% |
| Q4 2022 | $1,626,656 | +164.9% | 33,924 | +32.7% | 0.01% | +175.0% |
| Q3 2022 | $614,000 | +14.3% | 25,571 | +3.6% | 0.00% | 0.0% |
| Q2 2022 | $537,000 | +5.1% | 24,672 | +16.5% | 0.00% | +33.3% |
| Q1 2022 | $511,000 | 0.0% | 21,170 | -1.4% | 0.00% | 0.0% |
| Q4 2021 | $511,000 | -8.9% | 21,467 | -2.9% | 0.00% | 0.0% |
| Q3 2021 | $561,000 | +12.0% | 22,110 | -0.7% | 0.00% | +50.0% |
| Q2 2021 | $501,000 | +50.5% | 22,272 | +31.9% | 0.00% | +100.0% |
| Q1 2021 | $333,000 | +18.5% | 16,885 | +59.5% | 0.00% | 0.0% |
| Q4 2020 | $281,000 | -47.8% | 10,586 | -2.8% | 0.00% | -66.7% |
| Q3 2020 | $538,000 | – | 10,889 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 1,049,893 | $53,523,545 | 17.09% |
| Pivotal bioVenture Partners Investment Advisor LLC | 793,036 | $40,429,128 | 16.12% |
| Kynam Capital Management, LP | 1,302,407 | $66,396,709 | 10.86% |
| RA Capital Management | 7,891,254 | $402,296,129 | 7.92% |
| COMMODORE CAPITAL LP | 1,100,000 | $56,078,000 | 6.56% |
| GREAT POINT PARTNERS LLC | 531,211 | $27,081,137 | 4.93% |
| ACUTA CAPITAL PARTNERS, LLC | 121,022 | $6,169,702 | 4.14% |
| Frazier Life Sciences Management, L.P. | 1,164,405 | $59,361,367 | 3.94% |
| Novo Holdings A/S | 845,000 | $43,078,100 | 3.18% |
| BRAIDWELL LP | 1,619,553 | $82,564,812 | 2.61% |